---
title: "Ex-Vivo Tumor Studies"
canonical: "https://www.pharmalegacy.com/indications/oncology-immuno-oncology/ex-vivo-tumor-studies/"
lastmod: "2025-07-07T15:28:34+00:00"
generator: "llm-mirrors/1.0.19"
---

Around 90% of drugs that look promising in in vivo trials end up failing in clinical settings; 0.02% of all drugs developed eventually end up on the market. At PharmaLegacy, we understand these numbers are intimidating. We aim at mitigating all risks your pipelines have, and improving these numbers. With our ex-vivo tumor study models, notably our tumor histopathology studies, 3D tumor tissue cultures and tumor microenvironment studies, we at PharmaLegacy are confident that we can take your pipelines from start to finish.
Put your trust in the right CRO. Put your trust in PharmaLegacy.